Integrated Bioinformatic Analysis of Diabetes Mellitus and Cardiovascular Diseases' Shared Molecular Mechanisms

Integrated Bioinformatic Analysis of Diabetes Mellitus and
Cardiovascular Diseases' Shared Molecular Mechanisms

Introduction: Cardiovascular Diseases (CVDs) and Type 2 Diabetes Mellitus (T2DM) are
closely interconnected, sharing several molecular mechanisms. Notably, insulin resistance
and inflammation are common pathophysiological factors that contribute to the progression
of both conditions. Given that CVD is the leading cause of mortality in individuals with
T2DM, this study aims to explore these shared mechanisms to provide insights that could
inform the development of more targeted therapeutic strategies.

Aim: The primary aim of this research is to identify the shared molecular pathways and
mechanisms between CVDs and T2DM. Specifically, this study focuses on uncovering
differentially expressed genes (DEGs), curated pathways, common miRNAs, and other
related molecular factors that could contribute to the co-occurrence of these diseases.

Methods: A bioinformatic approach was utilized to analyze gene expression data, leading to
the identification of DEGs and the isolation of curated pathways and genes. The analysis was alsoextended to miRNAs and other chemicals associated with both CVDs and T2DM.

Results: This study identified four differentially expressed genes (DEGs) and one shared
miRNA, hsa-mir-223, which are potentially implicated in the development of both CVDs and
T2DM. Additionally, the analysis uncovered 6 curated genes, 37 curated chemicals, and 253
inferred pathways. The statistical analysis confirmed the significance of these findings, with
the DEGs showing a strong correlation (p < 0.05) between the two diseases.

Conclusion: The results highlight potential molecular interconnections between CVDs and
T2DM, providing a foundation for further research into the development of targeted
therapies. The findings underscore the importance of collaborative efforts among researchers,
clinicians, and the pharmaceutical industry to advance early detection, improve drug
development, and refine treatment strategies for individuals at risk or suffering from both
conditions.